Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)
Radiolabelled 14C-canagliflozin · 1 trial · 1 indication
Plasma concentrations of canagliflozin (JNJ-28431754) will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
Urine concentrations of canagliflozin (JNJ-28431754) will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
The total radioactivity excreted in the urine will be expressed as a percentage of the administered dose of canagliflozin (JNJ-28431754) and will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
The total radioactivity excreted in the feces will be expressed as a percentage of the administered dose of canagliflozin (JNJ-28431754) and will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
The total radioactivity in blood will be used to determine pharmacokinetic parameters for canagliflozin (JNJ-28431754) (measurements describing how the body affects the drug).
The total radioactivity in plasma will be used to determine pharmacokinetic parameters for canagliflozin (JNJ-28431754) (measurements describing how the body affects the drug).
Concentrations of canagliflozin (JNJ-28431754) metabolites in plasma will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body).
Concentrations of canagliflozin (JNJ-28431754) metabolites in urine will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body).
Concentrations of canagliflozin (JNJ-28431754) metabolites in feces will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body).
| Arm | Type | Description |
|---|---|---|
| Radiolabeled 14C-canagliflozin | EXPERIMENTAL | Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1. |
| Name | Type | Description |
|---|---|---|
| Radiolabelled 14C-canagliflozin (14C-JNJ-28431754) | DRUG | A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1. |
Inclusion Criteria: * Body Mass Index (BMI) (weight \[kg\]/height \[m2\]) between 18 and 30 kg/m2 * Non-smoker Exclusion Criteria: * Exposure to radiation for professional or medical reasons (except dental x-rays and x-rays of thorax and bone skeleton, excluding spinal column) in the past 12 mont...
Radiolabelled 14C-canagliflozin is a carbon-14 labeled form of canagliflozin, a small molecule developed by Johnson & Johnson. It is used in clinical research to study how the body absorbs, metabolizes, and excretes canagliflozin. It is not a marketed therapeutic product and is not approved for any indication.
Radiolabelled 14C-canagliflozin is developed by Johnson & Johnson, which trades under the ticker JNJ. The compound is a radiolabeled research form of canagliflozin, also known as JNJ-28431754, and was studied in a company-sponsored clinical trial.
Radiolabelled 14C-canagliflozin is in Phase 1 development. It has been evaluated in a single completed Phase 1 study, and no active trials are ongoing. It is an investigational research compound and is not approved by the FDA for any use.
Radiolabelled 14C-canagliflozin has been studied in one completed Phase 1 trial, NCT01791231, titled a study to investigate the absorption, metabolism, and excretion of canagliflozin (JNJ-28431754) in healthy male volunteers. The trial enrolled 6 participants in Belgium and has completed.
Yes. Radiolabelled 14C-canagliflozin is also known as 14C-JNJ-28431754. Both names refer to the same carbon-14 labeled research form of canagliflozin, the small molecule developed by Johnson & Johnson for studying drug absorption, metabolism, and excretion.